Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 6/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 5/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28469104 | 0.98 | L3MBTL1 (0.42) | L3MBTL1CHRNB2CHRNA4CHRNA7SSTR4 | |
| SCHEMBL2146650 | 0.84 | L3MBTL1 (0.42) | L3MBTL1SSTR4POLBKMT2AALDH1A1 | |
| SCHEMBL2146657 | 0.84 | L3MBTL1 (0.42) | L3MBTL1SSTR4POLBKMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2146149 | 0.82 | L3MBTL1 (0.41) | L3MBTL1SSTR4POLBKMT2AALDH1A1 | |
| SCHEMBL2990143 | 0.82 | CHRNB2 (0.65) | L3MBTL1CHRNB2CHRNA4CHRNA7CHRNB4 | |
| Hydrochloric Acid SCHEMBL2146143 | 0.82 | L3MBTL1 (0.41) | L3MBTL1SSTR4POLBKMT2AALDH1A1 | |
| SCHEMBL21214136 | 0.81 | SLC6A1 (0.53) | L3MBTL1SSTR4KMT2ALMNASMN1; SMN2 | |
| SCHEMBL21214016 | 0.81 | SLC6A1 (0.53) | L3MBTL1SSTR4KMT2ALMNASMN1; SMN2 | |
| SCHEMBL21214198 | 0.81 | SLC6A1 (0.53) | L3MBTL1SSTR4KMT2ALMNASMN1; SMN2 | |
| SCHEMBL29215860 | 0.78 | SSTR4 (0.62) | SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-14 | — | — | US | disclosed |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-14 | — | — | US | disclosed |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2022-09-08 | — | — | US | disclosed |
| US-11130741-B2 | Anti-infective heterocyclic compounds and uses thereof | BIOIMICS AB (SE) | 2021-09-28 | — | — | US | disclosed |
| WO-2020257180-A1 | AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20190233384-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2019-08-01 | — | — | US | disclosed |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2018-07-12 | — | — | US | disclosed |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233384-A1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | ELANE, MPO, NISCH | L3MBTL1 3547/4885CHRNB2 4881/4885CHRNA4 4885/4885 |
| US-20230286983-A1 | PYRIDINE-1,5-DIONES EXHIBITING MNK INHIBITION AND THEIR METHOD OF USE | DMPK, PDXK, NIM1K | L3MBTL1 4162/4885CHRNB2 888/4885CHRNA4 1623/4885 |
| US-11130741-B2 | Anti-infective heterocyclic compounds and uses thereof | ELANE, MPO, NISCH | L3MBTL1 3547/4885CHRNB2 4881/4885CHRNA4 4885/4885 |
| US-20180193315-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, KAT2A | L3MBTL1 3796/4885CHRNB2 3585/4885CHRNA4 3779/4885 |
| US-20220280509-A1 | AZA-QUINOLINE COMPOUNDS AND USES THEREOF | EZH2, BMI1, EED | L3MBTL1 3269/4885CHRNB2 1653/4885CHRNA4 2341/4885 |
| US-20180071262-A1 | SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE | KAT2B, HDAC1, HDAC9 | L3MBTL1 3671/4885CHRNB2 3662/4885CHRNA4 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.